-

Doximity Announces Fiscal 2026 Second Quarter Financial Results

Total revenues of $168.5 million, up 23% year-over-year

Operating cash flow of $93.9 million, up 37% year-over-year

Free cash flow of $91.6 million, up 37% year-over-year

SAN FRANCISCO--(BUSINESS WIRE)--Doximity, Inc. (NYSE: DOCS), the leading digital platform for U.S. medical professionals, today announced results of its fiscal 2026 second quarter ended September 30, 2025.

“Our platform continues to grow with new AI tools to save physicians’ time,” said Jeff Tangney, co-founder and CEO of Doximity. “In Q2, a record 650,000 prescribers used our workflow tools to better serve their patients, while our AI Scribe and DoxGPT users grew over 50% from the prior quarter.”

Fiscal 2026 Second Quarter Financial Highlights

All comparisons, unless otherwise noted, are to the three months ended September 30, 2024.

  • Revenue: Revenue of $168.5 million, versus $136.8 million, an increase of 23% year-over-year.
  • Net income and non-GAAP net income: Net income of $62.1 million, versus $44.2 million, representing a margin of 36.8%, versus 32.3%. Non-GAAP net income of $90.0 million, versus $61.1 million, representing a margin of 53.4%, versus 44.7%.
  • Adjusted EBITDA: Adjusted EBITDA of $100.8 million, versus $76.1 million, an increase of 32% year-over-year, representing adjusted EBITDA margins of 59.8%, versus 55.7%.
  • Diluted net income per share and non-GAAP diluted net income per share: Diluted net income per share was $0.31, versus $0.22, while non-GAAP diluted net income per share was $0.45, versus $0.30.
  • Operating cash flow and free cash flow: Operating cash flow of $93.9 million, versus $68.3 million, an increase of 37% year-over-year, and free cash flow of $91.6 million, versus $66.8 million, an increase of 37% year-over-year.

Financial Outlook

Doximity is providing guidance for its fiscal third quarter ending December 31, 2025 as follows:

  • Revenue between $180 million and $181 million.
  • Adjusted EBITDA between $103 million and $104 million.

Doximity is updating guidance for its fiscal year ending March 31, 2026 as follows:

  • Revenue between $640 million and $646 million.
  • Adjusted EBITDA between $351 million and $357 million.

Conference Call Information

Doximity posted prepared remarks on its investor relations website at https://investors.doximity.com. Doximity will host a webcast today at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) to discuss these financial results. To listen to a live audio webcast, please visit the Company’s Investor Relations page at https://investors.doximity.com. The archived webcast will be available on the Company’s Investor Relations page shortly after the call.

About Doximity

Founded in 2010, Doximity is the leading digital platform for U.S. medical professionals. The company's network members include more than 80% of U.S. physicians across all specialties and practice areas. Doximity provides its verified clinical membership with digital tools built for medicine, enabling them to collaborate with colleagues, stay current on medical news and research, manage their careers and on-call schedules, streamline documentation and administrative paperwork, and conduct virtual patient visits. With new AI-powered clinical reference and search capabilities, Doximity also helps doctors access trusted, peer-reviewed information and medical literature. Doximity's mission is to help doctors be more productive so they can provide better care for their patients.

Forward-Looking Statements

Statements we make in this press release may include statements which are not historical facts and are considered forward-looking within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act, which are usually identified by the use of words such as “anticipates,” “believes,” “estimates,” “expects,” “intends,” “may,” “plans,” “projects,” “seeks,” “should,” “will,” and variations of such words or similar expressions. We intend these forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act and Section 21E of the Securities Exchange Act and are making this statement for purposes of complying with those safe harbor provisions. These forward-looking statements reflect our current views about our plans, intentions, expectations, strategies and prospects, which are based on the information currently available to us and on assumptions we have made. Although we believe that our plans, intentions, expectations, strategies and prospects as reflected in or suggested by those forward-looking statements are reasonable, we can give no assurance that the plans, intentions, expectations, or strategies will be attained or achieved. Furthermore, actual results may differ materially from those described in the forward-looking statements and will be affected by a variety of risks and factors including (i) the timing and scope of anticipated stock repurchases; (ii) the impact of uncertainty in the current economic environment and macroeconomic uncertainty; (iii) our ability to retain existing members or add new members to our platform and maintain or grow their engagement with our platform; (iv) our ability to attract new customers or retain existing customers; (v) the impact of our prioritization of our members’ interests; (vi) breaches in our security measures or unauthorized access to members’ data; (vii) our ability to maintain or manage our growth, and other risks and factors that are beyond our control including, without limitation, those set forth in the section entitled “Risk Factors” in our Annual Report on Form 10-K for the fiscal year ended March 31, 2025 and as may be updated in any subsequent Quarterly Reports on Form 10-Q. Moreover, we operate in a very competitive and rapidly changing environment. New risks and uncertainties emerge from time to time, and it is not possible for us to predict all risks and uncertainties that could cause actual results to differ materially from those contained in our forward-looking statements. The forward-looking statements made in this press release relate only to management’s beliefs and assumptions as of this date. We assume no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

DOXIMITY, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(in thousands)
(unaudited)

 

 

September 30, 2025

 

March 31, 2025

Assets

 

 

 

Current assets:

 

 

 

Cash and cash equivalents

$

169,249

 

$

209,614

Marketable securities

 

709,118

 

 

706,050

Accounts receivable, net

 

129,306

 

 

128,354

Prepaid expenses and other current assets

 

84,527

 

 

44,602

Total current assets

 

1,092,200

 

 

1,088,620

Property and equipment, net

 

15,712

 

 

13,656

Deferred income tax assets

 

15,074

 

 

60,014

Operating lease right-of-use assets

 

7,982

 

 

8,886

Intangible assets, net

 

39,143

 

 

23,072

Goodwill

 

84,973

 

 

67,940

Other assets

 

2,025

 

 

2,121

Total assets

$

1,257,109

 

$

1,264,309

Liabilities and Stockholders’ Equity

 

 

 

Current liabilities:

 

 

 

Accounts payable

$

4,391

 

$

1,356

Accrued expenses and other current liabilities

 

33,722

 

 

38,405

Deferred revenue, current

 

100,034

 

 

114,285

Operating lease liabilities, current

 

2,123

 

 

2,211

Total current liabilities

 

140,270

 

 

156,257

Deferred revenue, non-current

 

263

 

 

280

Operating lease liabilities, non-current

 

9,146

 

 

10,185

Contingent earn-out consideration liability, non-current

 

 

 

5,579

Other liabilities, non-current

 

11,899

 

 

9,383

Total liabilities

 

161,578

 

 

181,684

Stockholders' Equity

 

 

 

Preferred stock

 

 

 

Common stock

 

188

 

 

189

Additional paid-in capital

 

936,176

 

 

894,225

Accumulated other comprehensive income

 

1,477

 

 

1,323

Retained earnings

 

157,690

 

 

186,888

Total stockholders’ equity

 

1,095,531

 

 

1,082,625

Total liabilities and stockholders’ equity

$

1,257,109

 

$

1,264,309

DOXIMITY, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(in thousands, except per share data)
(unaudited)

 

 

Three Months Ended
September 30,

 

Six Months Ended
September 30,

 

2025

 

2024

 

2025

 

2024

Revenue

$

168,525

 

$

136,832

 

$

314,438

 

$

263,508

Cost of revenue(1)

 

16,425

 

 

13,676

 

 

32,218

 

 

27,226

Gross profit

 

152,100

 

 

123,156

 

 

282,220

 

 

236,282

Operating expenses(1):

 

 

 

 

 

 

 

Research and development

 

30,202

 

 

23,240

 

 

57,001

 

 

45,814

Sales and marketing

 

39,168

 

 

34,367

 

 

75,533

 

 

69,611

General and administrative

 

19,049

 

 

10,103

 

 

31,488

 

 

19,358

Impairment charge

 

 

 

2,304

 

 

 

 

2,304

Total operating expenses

 

88,419

 

 

70,014

 

 

164,022

 

 

137,087

Income from operations

 

63,681

 

 

53,142

 

 

118,198

 

 

99,195

Other income, net

 

9,258

 

 

9,029

 

 

18,888

 

 

16,145

Income before income taxes

 

72,939

 

 

62,171

 

 

137,086

 

 

115,340

Provision for income taxes

 

10,880

 

 

18,017

 

 

21,707

 

 

29,809

Net income

$

62,059

 

$

44,154

 

$

115,379

 

$

85,531

Net income per share attributable to Class A and Class B common stockholders:

 

 

 

 

 

 

 

Basic

$

0.33

 

$

0.24

 

$

0.61

 

$

0.46

Diluted

$

0.31

 

$

0.22

 

$

0.57

 

$

0.43

Weighted-average shares used in computing net income per share attributable to Class A and Class B common stockholders:

 

 

 

 

 

 

 

Basic

 

187,705

 

 

186,252

 

 

187,844

 

 

185,933

Diluted

 

200,745

 

 

200,407

 

 

200,952

 

 

199,818

(1) 

 

Costs and expenses include stock-based compensation expense as follows (in thousands):

 

Three Months Ended
September 30,

 

Six Months Ended
September 30,

 

2025

 

2024

 

2025

 

2024

Cost of revenue

$

2,844

 

$

2,661

 

$

5,824

 

$

5,555

Research and development

 

9,862

 

 

5,447

 

 

16,511

 

 

10,131

Sales and marketing

 

10,508

 

 

6,808

 

 

18,218

 

 

13,394

General and administrative

 

6,260

 

 

2,952

 

 

10,786

 

 

5,878

Total stock-based compensation expense

$

29,474

 

$

17,868

 

$

51,339

 

$

34,958

DOXIMITY, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(in thousands)
(unaudited)

 

 

Three Months Ended
September 30,

 

Six Months Ended
September 30,

 

2025

 

2024

 

2025

 

2024

Cash flows from operating activities

 

 

 

 

 

 

 

Net income

$

62,059

 

 

$

44,154

 

 

$

115,379

 

 

$

85,531

 

Adjustments to reconcile net income to net cash provided by operating activities:

 

 

 

 

 

 

 

Depreciation and amortization

 

3,469

 

 

 

2,613

 

 

 

6,263

 

 

 

5,175

 

Deferred income taxes

 

 

 

 

204

 

 

 

 

 

 

204

 

Stock-based compensation, net of amounts capitalized

 

29,474

 

 

 

17,868

 

 

 

51,339

 

 

 

34,958

 

Non-cash lease expense

 

454

 

 

 

470

 

 

 

904

 

 

 

951

 

Accretion of discount on marketable securities, net

 

(2,199

)

 

 

(3,008

)

 

 

(4,687

)

 

 

(5,368

)

Amortization of deferred contract costs

 

2,876

 

 

 

2,033

 

 

 

6,772

 

 

 

4,759

 

Impairment of long-lived assets

 

 

 

 

2,304

 

 

 

 

 

 

2,304

 

Other

 

294

 

 

 

414

 

 

 

(114

)

 

 

(122

)

Changes in operating assets and liabilities:

 

 

 

 

 

 

 

Accounts receivable

 

12,396

 

 

 

(4,106

)

 

 

(985

)

 

 

(23,478

)

Prepaid expenses and other assets

 

7,685

 

 

 

9,488

 

 

 

3,451

 

 

 

19,948

 

Deferred contract costs

 

(2,584

)

 

 

(1,785

)

 

 

(4,549

)

 

 

(3,216

)

Accounts payable, accrued expenses and other liabilities

 

(2,168

)

 

 

7,396

 

 

 

(2,333

)

 

 

(5,546

)

Deferred revenue

 

(17,241

)

 

 

(9,161

)

 

 

(14,268

)

 

 

(5,457

)

Operating lease liabilities

 

(571

)

 

 

(538

)

 

 

(1,127

)

 

 

(1,054

)

Net cash provided by operating activities

 

93,944

 

 

 

68,346

 

 

 

156,045

 

 

 

109,589

 

Cash flows from investing activities

 

 

 

 

 

 

 

Cash paid for acquisition

 

(26,528

)

 

 

 

 

 

(26,528

)

 

 

 

Internal-use software development costs

 

(2,369

)

 

 

(1,543

)

 

 

(4,335

)

 

 

(3,247

)

Purchases of marketable securities

 

(128,266

)

 

 

(197,395

)

 

 

(268,200

)

 

 

(367,808

)

Maturities of marketable securities

 

125,452

 

 

 

215,855

 

 

 

270,031

 

 

 

417,913

 

Sales of marketable securities

 

 

 

 

7,241

 

 

 

 

 

 

7,241

 

Net cash provided by (used in) investing activities

 

(31,711

)

 

 

24,158

 

 

 

(29,032

)

 

 

54,099

 

Cash flows from financing activities

 

 

 

 

 

 

 

Proceeds from issuance of common stock upon exercise of stock options and common stock warrants

 

2,398

 

 

 

7,692

 

 

 

4,796

 

 

 

10,243

 

Proceeds from issuance of common stock in connection with the employee stock purchase plan

 

1,816

 

 

 

1,422

 

 

 

1,816

 

 

 

1,422

 

Taxes paid related to net share settlement of equity awards

 

(12,566

)

 

 

(5,828

)

 

 

(24,493

)

 

 

(8,222

)

Repurchase of common stock

 

(21,893

)

 

 

(22,984

)

 

 

(144,248

)

 

 

(74,198

)

Payment of contingent consideration related to a business combination

 

 

 

 

 

 

 

(5,249

)

 

 

(5,470

)

Net cash used in financing activities

 

(30,245

)

 

 

(19,698

)

 

 

(167,378

)

 

 

(76,225

)

Net increase (decrease) in cash and cash equivalents

 

31,988

 

 

 

72,806

 

 

 

(40,365

)

 

 

87,463

 

Cash and cash equivalents, beginning of period

 

137,261

 

 

 

111,442

 

 

 

209,614

 

 

 

96,785

 

Cash and cash equivalents, end of period

$

169,249

 

 

$

184,248

 

 

$

169,249

 

 

$

184,248

 

Supplemental disclosures of cash flow information

 

 

 

 

 

 

 

Cash paid for taxes, net of refunds

$

14,369

 

 

$

9,078

 

 

$

19,347

 

 

$

21,985

 

Non-GAAP Financial Measures

To supplement our condensed consolidated financial statements, which are prepared and presented in accordance with accounting principles generally accepted in the United States (“GAAP”), the Company uses the following non-GAAP measures of financial performance:

  • Non-GAAP gross profit, non-GAAP gross margin, non-GAAP operating income, non-GAAP net income, non-GAAP net income margin, and non-GAAP basic and diluted net income per common share: We exclude the effect of acquisition and other related expenses, stock-based compensation expense, amortization of acquired intangible assets, impairment charge, legal fees associated with certain non-ordinary course legal matters including the shareholder class action litigation, and change in fair value of contingent earn-out consideration liability from non-GAAP gross profit, non-GAAP gross margin and non-GAAP operating income. Non-GAAP net income and non-GAAP net income margin are further adjusted for estimated income tax on such adjustments. We calculate income taxes on the adjustments by applying an estimated annual effective tax rate to the adjustments. Non-GAAP basic and diluted net income per common share is non-GAAP net income attributable to common stockholders divided by the weighted average number of shares. For both basic and diluted non-GAAP net income per share, the weighted average shares we use in computing non-GAAP net income per share is equal to our GAAP weighted average shares. Non-GAAP gross margin represents non-GAAP gross profit as a percentage of revenue and non-GAAP net income margin represents non-GAAP net income as a percentage of revenue.
  • Adjusted EBITDA and adjusted EBITDA margin: We define adjusted EBITDA as net income before interest, income taxes, depreciation, and amortization, and as further adjusted for acquisition and other related expenses, stock-based compensation expense, impairment charge, legal fees associated with certain non-ordinary course legal matters including the shareholder class action litigation, change in fair value of contingent earn-out consideration liability, and other income, net. Net income margin represents net income as a percentage of revenue and adjusted EBITDA margin represents adjusted EBITDA as a percentage of revenue.
  • Free cash flow: We calculate free cash flow as cash flow from operating activities less purchases of property and equipment and internal-use software development costs.

We use these non-GAAP financial measures internally for financial and operational decision-making purposes and as a means to evaluate period-to-period comparisons. Non-GAAP financial measures are not meant to be considered in isolation or as a substitute for comparable GAAP financial measures and should be read only in conjunction with our condensed consolidated financial statements prepared in accordance with GAAP. Our presentation of non-GAAP financial measures may not be comparable to similar measures used by other companies. We encourage investors to carefully consider our results under GAAP, as well as our supplemental non-GAAP information and the reconciliation between these presentations, to more fully understand our business. Please see the tables included at the end of this release for the reconciliation of GAAP to non-GAAP results.

Key Business Metrics

  • Net revenue retention rate: Net revenue retention rate is calculated by taking the trailing 12-month (“TTM”) subscription-based revenue from our customers that had revenue in the prior TTM period and dividing that by the total subscription-based revenue for the prior TTM period. For the purposes of this calculation, subscription revenue excludes subscriptions for individuals and small practices and other non-recurring items. Our net revenue retention rate compares our subscription revenue from the same set of customers across comparable periods, and reflects customer renewals, expansion, contraction, and churn. Our net revenue retention rate is directly tied to our revenue growth rate and thus fluctuates as that growth rate fluctuates.
  • Customers with trailing 12-month subscription revenue greater than $500,000: The number of customers with TTM subscription revenue greater than $500,000 is a key indicator of the scale of our business, and is calculated by counting the number of customers that contributed more than $500,000 in subscription revenue in the TTM period. Our customer count is subject to adjustments for acquisitions, consolidations, spin-offs, and other market activity, and we present our total customer count for historical periods reflecting these adjustments. 

Reconciliation of GAAP to Non-GAAP Financial Measures

The following tables reconcile the specific items excluded from GAAP metrics in the calculation of non-GAAP metrics for the periods shown below:

 

Three Months Ended
September 30,

 

Six Months Ended
September 30,

 

2025

 

2024

 

2025

 

2024

 

(unaudited)

 

(in thousands, except percentages)

Net income

$

62,059

 

 

$

44,154

 

 

$

115,379

 

 

$

85,531

 

Adjusted to exclude the following:

 

 

 

 

 

 

 

Acquisition and other related expenses

 

1,188

 

 

 

 

 

 

1,616

 

 

 

 

Stock-based compensation

 

29,474

 

 

 

17,868

 

 

 

51,339

 

 

 

34,958

 

Depreciation and amortization

 

3,469

 

 

 

2,613

 

 

 

6,263

 

 

 

5,175

 

Provision for income taxes

 

10,880

 

 

 

18,017

 

 

 

21,707

 

 

 

29,809

 

Impairment charge

 

 

 

 

2,304

 

 

 

 

 

 

2,304

 

Change in fair value of contingent earn-out consideration liability

 

91

 

 

 

221

 

 

 

259

 

 

 

423

 

Legal expenses

 

2,927

 

 

 

 

 

 

2,927

 

 

 

 

Other income, net

 

(9,258

)

 

 

(9,029

)

 

 

(18,888

)

 

 

(16,145

)

Adjusted EBITDA

$

100,830

 

 

$

76,148

 

 

$

180,602

 

 

$

142,055

 

 

 

 

 

 

 

 

 

Revenue

$

168,525

 

 

$

136,832

 

 

$

314,438

 

 

$

263,508

 

Net income margin

 

36.8

%

 

 

32.3

%

 

 

36.7

%

 

 

32.5

%

Adjusted EBITDA margin

 

59.8

%

 

 

55.7

%

 

 

57.4

%

 

 

53.9

%

 

Three Months Ended
September 30,

 

Six Months Ended
September 30,

 

2025

 

2024

 

2025

 

2024

 

(unaudited)

 

(in thousands)

Net cash provided by operating activities

$

93,944

 

 

$

68,346

 

 

$

156,045

 

 

$

109,589

 

Internal-use software development costs

 

(2,369

)

 

 

(1,543

)

 

 

(4,335

)

 

 

(3,247

)

Free cash flow

$

91,575

 

 

$

66,803

 

 

$

151,710

 

 

$

106,342

 

Other cash flow components:

 

 

 

 

 

 

 

Net cash provided by (used in) investing activities

$

(31,711

)

 

$

24,158

 

 

$

(29,032

)

 

$

54,099

Net cash used in financing activities

$

(30,245

)

$

(19,698

)

$

(167,378

)

$

(76,225

)

 

Three Months Ended
September 30,

 

Six Months Ended
September 30,

 

2025

 

2024

 

2025

 

2024

 

(unaudited)

 

(in thousands, except per share data and percentages)

GAAP cost of revenue

$

16,425

 

 

$

13,676

 

 

$

32,218

 

 

$

27,226

 

Adjusted to exclude the following:

 

 

 

 

 

 

 

Stock-based compensation

 

(2,844

)

 

 

(2,661

)

 

 

(5,824

)

 

 

(5,555

)

Non-GAAP cost of revenue

$

13,581

 

 

$

11,015

 

 

$

26,394

 

 

$

21,671

 

 

 

 

 

 

 

 

 

GAAP gross profit

$

152,100

 

 

$

123,156

 

 

$

282,220

 

 

$

236,282

 

Adjusted to exclude the following:

 

 

 

 

 

 

 

Stock-based compensation

 

2,844

 

 

 

2,661

 

 

 

5,824

 

 

 

5,555

 

Non-GAAP gross profit

$

154,944

 

 

$

125,817

 

 

$

288,044

 

 

$

241,837

 

 

 

 

 

 

 

 

 

GAAP gross margin

 

90.3

%

 

 

90.0

%

 

 

89.8

%

 

 

89.7

%

Non-GAAP gross margin

 

91.9

%

 

 

91.9

%

 

 

91.6

%

 

 

91.8

%

 

 

 

 

 

 

 

 

GAAP research and development expense

$

30,202

 

 

$

23,240

 

 

$

57,001

 

 

$

45,814

 

Adjusted to exclude the following:

 

 

 

 

 

 

 

Stock-based compensation

 

(9,862

)

 

 

(5,447

)

 

 

(16,511

)

 

 

(10,131

)

Amortization of acquired intangibles

 

(623

)

 

 

 

 

 

(623

)

 

 

 

Non-GAAP research and development expense

$

19,717

 

 

$

17,793

 

 

$

39,867

 

 

$

35,683

 

 

 

 

 

 

 

 

 

GAAP sales and marketing expense

$

39,168

 

 

$

34,367

 

 

$

75,533

 

 

$

69,611

 

Adjusted to exclude the following:

 

 

 

 

 

 

 

Stock-based compensation

 

(10,508

)

 

 

(6,808

)

 

 

(18,218

)

 

 

(13,394

)

Amortization of acquired intangibles

 

(1,002

)

 

 

(1,061

)

 

 

(2,004

)

 

 

(2,122

)

Change in fair value of contingent earn-out consideration liability

 

(91

)

 

 

(221

)

 

 

(259

)

 

 

(423

)

Non-GAAP sales and marketing expense

$

27,567

 

 

$

26,277

 

 

$

55,052

 

 

$

53,672

 

 

 

 

 

 

 

 

 

GAAP general and administrative expense

$

19,049

 

 

$

10,103

 

 

$

31,488

 

 

$

19,358

 

Adjusted to exclude the following:

 

 

 

 

 

 

 

Acquisition and other related expenses

 

(1,188

)

 

 

 

 

 

(1,616

)

 

 

 

Stock-based compensation

 

(6,260

)

 

 

(2,952

)

 

 

(10,786

)

 

 

(5,878

)

Legal expenses

 

(2,927

)

 

 

 

 

 

(2,927

)

 

 

 

Non-GAAP general and administrative expense

$

8,674

 

 

$

7,151

 

 

$

16,159

 

 

$

13,480

 

 

 

 

 

 

 

 

 

GAAP operating expense

$

88,419

 

 

$

70,014

 

 

$

164,022

 

 

$

137,087

 

Adjusted to exclude the following:

 

 

 

 

 

 

 

Acquisition and other related expenses

 

(1,188

)

 

 

 

 

 

(1,616

)

 

 

 

Stock-based compensation

 

(26,630

)

 

 

(15,207

)

 

 

(45,515

)

 

 

(29,403

)

Amortization of acquired intangibles

 

(1,625

)

 

 

(1,061

)

 

 

(2,627

)

 

 

(2,122

)

Change in fair value of contingent earn-out consideration liability

 

(91

)

 

 

(221

)

 

 

(259

)

 

 

(423

)

Legal expenses

 

(2,927

)

 

 

 

 

 

(2,927

)

 

 

 

Impairment charge

 

 

 

 

(2,304

)

 

 

 

 

 

(2,304

)

Non-GAAP operating expense

$

55,958

 

 

$

51,221

 

 

$

111,078

 

 

$

102,835

 

GAAP operating income

$

63,681

 

 

$

53,142

 

 

$

118,198

 

 

$

99,195

 

Adjusted to exclude the following:

 

 

 

 

 

 

 

Acquisition and other related expenses

 

1,188

 

 

 

 

 

 

1,616

 

 

 

 

Stock-based compensation

 

29,474

 

 

 

17,868

 

 

 

51,339

 

 

 

34,958

 

Amortization of acquired intangibles

 

1,625

 

 

 

1,061

 

 

 

2,627

 

 

 

2,122

 

Change in fair value of contingent earn-out consideration liability

 

91

 

 

 

221

 

 

 

259

 

 

 

423

 

Legal expenses

 

2,927

 

 

 

 

 

 

2,927

 

 

 

 

Impairment charge

 

 

 

 

2,304

 

 

 

 

 

 

2,304

 

Non-GAAP operating income

$

98,986

 

 

$

74,596

 

 

$

176,966

 

 

$

139,002

 

 

 

 

 

 

 

 

 

GAAP net income

$

62,059

 

 

$

44,154

 

 

$

115,379

 

 

$

85,531

 

Adjusted to exclude the following:

 

 

 

 

 

 

 

Acquisition and other related expenses

 

1,188

 

 

 

 

 

 

1,616

 

 

 

 

Stock-based compensation

 

29,474

 

 

 

17,868

 

 

 

51,339

 

 

 

34,958

 

Amortization of acquired intangibles

 

1,625

 

 

 

1,061

 

 

 

2,627

 

 

 

2,122

 

Change in fair value of contingent earn-out consideration liability

 

91

 

 

 

221

 

 

 

259

 

 

 

423

 

Legal expenses

 

2,927

 

 

 

 

 

 

2,927

 

 

 

 

Impairment charge

 

 

 

 

2,304

 

 

 

 

 

 

2,304

 

Income tax effect of non-GAAP adjustments (1)

 

(7,414

)

 

 

(4,505

)

 

 

(12,341

)

 

 

(8,359

)

Non-GAAP net income

$

89,950

 

 

$

61,103

 

 

$

161,806

 

 

$

116,979

 

Non-GAAP net income margin

 

53.4

%

 

 

44.7

%

 

 

51.5

%

 

 

44.4

%

 

 

 

 

 

 

 

 

Weighted-average shares used in computing net income per share attributable to Class A and Class B common stockholders:

 

 

 

 

 

 

 

Basic

 

187,705

 

 

 

186,252

 

 

 

187,844

 

 

 

185,933

 

Diluted

 

200,745

 

 

 

200,407

 

 

 

200,952

 

 

 

199,818

 

 

 

 

 

 

 

 

 

Non-GAAP net income per share attributable to Class A and Class B stockholders:

 

 

 

 

 

 

 

Basic

$

0.48

 

 

$

0.33

 

 

$

0.86

 

 

$

0.63

 

Diluted

$

0.45

 

 

$

0.30

 

 

$

0.81

 

 

$

0.59

 

(1)

 

For the three and six months ended September 30, 2025 and 2024, management used an estimated annual effective non-GAAP tax rate of 21.0%.

 

Contacts

Investor Relations Contact:
Perry Gold
ir@doximity.com

Media Contact:
Amanda Cox
pr@doximity.com

Doximity

NYSE:DOCS

Release Versions

Contacts

Investor Relations Contact:
Perry Gold
ir@doximity.com

Media Contact:
Amanda Cox
pr@doximity.com

More News From Doximity

Doximity to Release Fiscal 2026 Second Quarter Results on November 6, 2025

SAN FRANCISCO--(BUSINESS WIRE)--Doximity, Inc. (NYSE:DOCS), the leading digital platform for U.S. medical professionals, today announced it will report financial results for its fiscal second quarter ended September 30, 2025 after market close on November 6, 2025. Doximity will host a conference call and webcast at 2:00 p.m. PT (5:00 p.m. ET) to discuss the financial results. To listen to a live audio webcast, please visit the Company’s Investor Relations page at https://investors.doximity.com/...

Doximity Acquires Pathway, a Leader in AI Clinical Reference

SAN FRANCISCO--(BUSINESS WIRE)--Doximity, Inc. (NYSE: DOCS), the leading digital platform for U.S. medical professionals, today announced that it has acquired Pathway Medical Inc., a Montreal-based startup specializing in medical AI and evidence-based clinical reference. Physicians make up half of Pathway’s team. Over the past seven years, they’ve assembled one of the largest structured datasets in medicine—purpose-built for AI—spanning nearly every guideline, drug, and landmark trial across al...

Doximity Announces Fiscal 2026 First Quarter Financial Results

SAN FRANCISCO--(BUSINESS WIRE)--Doximity, Inc. (NYSE: DOCS), the leading digital platform for U.S. medical professionals, today announced results of its fiscal 2026 first quarter ended June 30, 2025. “We began our year with strong profit growth and record engagement across our newsfeed, workflow, and AI products,” said Jeff Tangney, co-founder and CEO of Doximity. “Our AI suite once again grew the fastest, up 5x year-over-year, while more than 630,000 prescribers used our workflow tools to save...
Back to Newsroom